Daniel L Hertz
University of Michigan Rogel Cancer Center · University of Michigan
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Daniel L Hertz as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 02:00 UTC. Open this list on ClinicalTrials.gov
- N/ANCT06915168 · CIPN Decision Aid for the Improvement of Chemotherapy Decision Making in Patients With Breast CancerUniversity of Michigan Rogel Cancer Center · recruiting · Breast Carcinoma · principal investigator
- Ph4NCT05691400 · Phase IV Multi-arm Study of CDK4/6 Pharmacokinetics in Healthy Volunteers With Known CYP3A4*22 GenotypeUniversity of Michigan Rogel Cancer Center · withdrawn · CYP3A4*22 · principal investigator
- Ph4NCT05183126 · Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With CancerUniversity of Michigan Rogel Cancer Center · recruiting · Breast Cancer, Metastatic Gastric Cancer, Esophageal Cancer · principal investigator
- N/ANCT02338115 · Defining an Exposure Target for Weekly Paclitaxel Infusion in Breast Cancer PatientsUniversity of Michigan Rogel Cancer Center · completed · Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 02:00 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Development of an Integrated Risk Prediction Model of Taxane-induced Peripheral NeuropathyR37CA277043 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · fiscal years 2023 to 2026 · $484,606 awarded in 2026Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 02:00 UTC. The ranking covers the 200 most relevant of 11 PubMed records, and a shared surname and initials can bring in a namesake. All 11 on PubMed
- Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy.Clin Cancer Res · 201648 citationsRCR 1.8
- In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles.Br J Clin Pharmacol · 201542 citationsRCR 1.7
- 29 citationsRCR 1.0
- Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221.J Natl Compr Canc Netw · 202327 citationsRCR 3.2
- Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients.Br J Cancer · 202220 citationsRCR 1.5
- Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptoms.Support Care Cancer · 202211 citationsRCR 0.9
- Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226.Br J Clin Pharmacol · 20169 citationsRCR 0.3
- Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole.Pharmacogenomics · 20198 citationsRCR 0.3
- Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity.Pharmacogenet Genomics · 20215 citationsRCR 0.4
- Pre-treatment amino acids and risk of paclitaxel-induced peripheral neuropathy in SWOG S0221.Cancer Chemother Pharmacol · 20243 citationsRCR 0.6